Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 dichloride plus exemestane and everolimus in HER2-negative, hormone receptor–positive breast cancer with bone metastases
jRCT2080222975Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2015
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
01
Overview
Phase 2 trial of radium-223 dichloride in breast cancer (2 arms), sponsored by Bayer. Primary endpoint: Symptomatic skeletal event-free survival. Started Oct 2015; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080222975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222975.